Joshi Ashish, Falodia Sushil, Kumar Naveen, Gupta Pawan, Khatri P C
Department of Gastroenterology, Sardar Patel Medical College, Bikaner, 334 001, India.
Department of General Medicine, Sardar Patel Medical College, Bikaner, 334 001, India.
Indian J Gastroenterol. 2018 May;37(3):243-247. doi: 10.1007/s12664-018-0857-6. Epub 2018 Jun 13.
Liver involvement in celiac disease (CD) is classified into autoimmune and cryptogenic. The association between CD and autoimmune liver diseases like autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis is well-established; however, the data on patients with cryptogenic cirrhosis, particularly from India, are scanty. So we did this study to find the prevalence of CD in patients with cryptogenic cirrhosis.
This was a prospective observational study, involving children of less than 18 years old attending Pediatric and Gastroenterology clinic with a diagnosis of cryptogenic cirrhosis. The patients were evaluated for CD and divided into two groups: chronic liver disease (CLD) with CD, and CLD without CD. Both the groups were followed up for 6 months. CLD with CD group was treated with gluten-free-diet (GFD) and CLD without CD group was followed up without any specific intervention except standard care of CLD.
Out of 84 patients, 11 (13.1%) were diagnosed as CLD with CD. There was an improvement in hemoglobin levels, liver function tests, and Child-Pugh score after initiation of GFD in CLD with CD group.
The prevalence of CD in cryptogenic cirrhosis was 13.1%. Screening for CD is recommended for cryptogenic cirrhosis. Hepatic functions improve with a GFD in CD patients with cirrhosis.
乳糜泻(CD)累及肝脏可分为自身免疫性和隐源性。CD与自身免疫性肝病如自身免疫性肝炎、原发性胆汁性肝硬化和原发性硬化性胆管炎之间的关联已得到充分证实;然而,关于隐源性肝硬化患者的数据,尤其是来自印度的数据却很匮乏。因此,我们开展了这项研究以确定隐源性肝硬化患者中CD的患病率。
这是一项前瞻性观察性研究,纳入年龄小于18岁、在儿科和胃肠病科门诊被诊断为隐源性肝硬化的儿童。对这些患者进行CD评估,并分为两组:合并CD的慢性肝病(CLD)组和不合并CD的CLD组。两组均随访6个月。合并CD的CLD组采用无麸质饮食(GFD)治疗,不合并CD的CLD组除了CLD的标准护理外未进行任何特殊干预,仅进行随访。
84例患者中,11例(13.1%)被诊断为合并CD的CLD。合并CD的CLD组开始GFD治疗后,血红蛋白水平、肝功能检查和Child-Pugh评分均有所改善。
隐源性肝硬化中CD的患病率为13.1%。建议对隐源性肝硬化患者进行CD筛查。肝硬化合并CD的患者采用GFD治疗可改善肝功能。